Jump to any asset
849 assets, updated daily
As of September 16, 2026, BioNTech SE (BNTX) trades at $96.69. CleaRank Financial AI rates it Buy with a fair value of $96.69, in line with the current price. Wall Street's consensus target is $126.35 across 20 analysts. RSI at 19 is in oversold territory, and the price is below its 50-day average of $96.94.
BioNTech SE (BNTX)
BioNTech SE NASDAQ
$96.69
-2.170 (-2.20%)
At close: Sep 15, 4:00 PM EDT
AI Analyst Consensus
66 / 100
BioNTech SE (BNTX) is currently trading at $96.69, below its 50-day and 200-day moving averages ($96.94 and $97.63), signaling a bearish technical trend. The company's revenue has declined significantly by -59.5%, and forward revenue estimates show continued contraction. Despite these challenges, Wall Street maintains a predominantly Buy-rated consensus, with 13 out of 20 analysts recommending Buy or Strong Buy, and a median price target of $126.35 indicating potential upside. The biotechnology firm's profitability remains a concern, with negative EPS of -7.78 and a substantial net profit margin of -63.64%. While the company has a low debt-to-equity ratio of 0.02, its current valuation metrics are distorted by negative earnings, making traditional P/E analysis inapplicable. The recent earnings report for the quarter ending June 2026 showed an EPS beat of $2.62 vs. an estimate of $2.51, but this was followed by a price drop, and prior quarters showed significant misses. The primary risk remains the continued revenue decline and the sustainability of its operations without a significant catalyst.
BNTX Price Analysis
Market Metrics
Open
$97.04
Day Range
$95.80 to $97.66
Prev Close
$98.86
Volume
590.4K
52-Week Range
$79.52 to $124.00
Market Cap
$24.29B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a significant premium to sector peers (+404%), suggesting market expectations for superior growth or market position.
BNTX Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 3 quarters, BNTX beat estimates 1 times. However, the stock fell 1 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
BNTX Analysis
Company's Health
2/5
12-Month Analyst Target
+30.67% Upside
Median of 20 analysts (12-month)
$126.35
AI Technical Analysis
BioNTech SE (BNTX) is exhibiting bearish momentum with its Relative Strength Index (RSI) at 19.48, indicating an oversold condition that could signal a potential reversal, though it also reflects strong selling pressure. The stock is trading below its 20-day, 50-day, and 200-day moving averages, with the 50-day SMA at $96.94 and the 200-day SMA at $97.63, reinforcing the current downtrend. The Moving Average Convergence Divergence (MACD) is at -0.117, also suggesting bearish momentum. Key support levels are being tested as the stock trades below its critical moving averages. Volume has been below average recently, with the latest volume at 590,400 compared to an average of 918,810, suggesting a lack of conviction from buyers. The current price action indicates that the stock is in a significant downtrend, and a sustained move above the 50-day SMA would be required to signal a potential shift in momentum.
ProTips
- BioNTech SE (BNTX) is trading at an oversold RSI of 19.48, suggesting a potential short-term bounce, but the stock remains below its 50-day and 200-day moving averages ($96.94 and $97.63), indicating a bearish trend. Consider waiting for a confirmed break above resistance levels before initiating new positions.
- With a significant revenue decline of -59.5% and projected further contractions, investors should closely monitor BioNTech SE's (BNTX) pipeline developments and upcoming clinical trial results for potential catalysts.
- Given the moderate insider selling and negative profitability, BioNTech SE (BNTX) presents a higher risk profile. A stop-loss order below the current oversold technical levels may be prudent for risk management.
Key Catalysts
Bullish
Positive Earnings Surprise in June 2026 Quarter
BioNTech SE (BNTX) reported an EPS beat of $2.62 vs. an estimate of $2.51 for the quarter ending June 2026, indicating operational performance exceeding analyst expectations for that period.
Source: Company Earnings ReportBearish
Moderate Insider Selling Activity
Insiders have sold a total of $20.6 million in BioNTech SE (BNTX) stock across three transactions, with no reported purchases, signaling a moderate sell signal and potentially reduced insider confidence.
Source: Insider Transaction FilingsBearish
Continued Revenue Decline and Negative Growth Projections
BioNTech SE (BNTX) reported a -59.5% revenue growth and faces projections for further revenue contraction, with current quarter estimates showing a -30.00% year-over-year decrease.
Source: Analyst EstimatesBullish
Strong Wall Street Buy Consensus and Upside Potential
Despite current challenges, 13 out of 20 analysts rate BioNTech SE (BNTX) as Buy or Strong Buy, with a median price target of $126.35, suggesting a 30.7% upside from the current price.
Source: Wall Street AnalystsMarket Outlook
BioNTech SE (BNTX) faces a challenging outlook, with current revenue trends and analyst estimates pointing towards continued contraction in the near to medium term. The company's next year revenue is projected to be $1.8 billion, with a slight growth of +0.00% year-over-year, and a concerning -64.5% compound annual growth rate projected over the next five years. The stock's current price of $96.69 is below key moving averages, and the oversold RSI suggests potential for a short-term bounce, but a sustained recovery will likely depend on new product catalysts or significant shifts in its clinical pipeline. Upside potential hinges on successful development and commercialization of new therapies beyond its COVID-19 vaccine, which has seen declining sales. Downside risks include continued revenue erosion, failure to gain regulatory approval for new drug candidates, and increased competition in the biotechnology sector. The moderate insider selling also adds a layer of caution, suggesting management's near-term confidence may be limited.
Key Statistics
| Market Cap | 24.29B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -7.78 |
| Dividend Yield | 0.00% |
| 52 Week High | 124.00 |
| 52 Week Low | 79.52 |
BioNTech SE (BNTX) presents a challenging fundamental picture, with a negative EPS of -7.78 and a net profit margin of -63.64%, indicating significant losses. The company's price-to-sales ratio stands at 9.37, which is considerably higher than the sector median of 3.7, suggesting a premium valuation relative to its sales, especially given its negative profitability. Its return on equity is -9.30%, further underscoring its current financial struggles. While the company maintains a very low debt-to-equity ratio of 0.02, providing some balance sheet stability, the steep revenue decline of -59.5% and projected further contractions in the coming quarters are major concerns. The current valuation appears stretched given the negative earnings and declining revenue trajectory, contrasting sharply with the sector's average revenue growth of 8.1%. Investors should carefully consider the high price-to-sales ratio in light of the company's current profitability and growth challenges.
Earnings & Growth Analysis
BioNTech SE (BNTX) most recently reported an EPS beat for the quarter ending June 2026, with actual EPS of $2.62 exceeding the estimate of $2.51 by 4.38%, though the stock price declined 2.44% on the news. This followed a miss in the prior quarter ending March 2026, where EPS was -1.95 against an estimate of -1.92, a surprise of -1.56%. Prior to that, the quarter ending March 2026 also saw an EPS miss of -0.33 versus an estimate of -0.25. The company's revenue is projected to decline significantly, with current quarter revenue estimates showing a -30.00% year-over-year decrease.
Key Risks
BioNTech SE (BNTX) faces significant risks including a sharp decline in revenue, down 59.5%, with further contractions projected in the coming quarters. The company is currently loss-making, with a negative EPS of -7.78 and a net profit margin of -63.64%, raising concerns about its long-term financial sustainability. Also, insider activity shows a moderate sell signal, with $20.6 million in sales and no reported purchases, indicating a lack of insider confidence in the near-term outlook.
Technical Indicators
| RSI (14) | 19.48 |
|---|---|
| MACD | -0.12 |
| SMA 50 | 96.94 |
| SMA 200 | 97.63 |
RSI
Oversold
SMA Cross
Neutral
Price vs SMA
Bearish
MACD
Bearish
Price is trading below the 50-day SMA, RSI at 19.5 suggests oversold conditions; potential bounce setup.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.30
Weak correlation
Nasdaq 100 (QQQ)
+0.25
Weak correlation
Bitcoin (BTC)
+0.24
Weak correlation
Gold (XAU)
+0.18
Weak correlation
Check Custom Correlation
How does any other asset move with BNTX? One year of daily closes, Pearson correlation.
Try
BNTX Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$94.76
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$96.69
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$87.34
MAX LOSS
-7.8%
Volatility-Adjusted Stop Loss
Calculated based on RSI (19.5) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$99.49
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$104.23
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$108.97
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
BNTX is classified as a high-volatility asset (Daily Vol: 4.74%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on September 16, 2026.Growth of $10,000
A $10,000 investment in BNTX in October 2019 would be worth about $67,900 today, compared with about $25,828 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BNTX today could grow to about $44,653 by 2036 in the base case, with a bull case near $338,766 and a bear case around $5,886. Projections are statistical simulations, not guarantees.
BNTX Stock Price Prediction: 2030
CleaRank's simulation projects a price near $176 for BNTX by 2030 in the base case, from $96.69 today (1.8x over 4 years). The downside path ends near $48.83. These are outcomes of a Monte Carlo simulation run on BNTX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $59.17 | $112 | $213 |
| 2028 | $52.70 | $130 | $323 |
| 2029 | $49.92 | $151 | $460 |
| 2030 | $48.83 | $176 | $634 |
| 2031 | $48.75 | $204 | $856 |
| 2032 | $49.39 | $237 | $1,140 |
| 2033 | $50.58 | $276 | $1,502 |
| 2034 | $52.25 | $320 | $1,961 |
| 2035 | $54.37 | $372 | $2,542 |
| 2036 | $56.91 | $432 | $3,276 |
Method: 10,000 simulated price paths using BNTX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. BNTX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
BNTX Insider Trading Analysis
Bought
None
No open-market buys
Sold
$20.6M
3 Transactions
Insiders
2
Active Traders
Avg Transaction
$6.9M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 4, 2026 | SAHIN UGUR MD
Chief Executive Officer
|
Sell | 76.5K | $7.9M |
| Sep 9, 2026 | SAHIN UGUR MD
Chief Executive Officer
|
Sell | 73.0K | $7.2M |
| Apr 22, 2026 | POETTING SIERK
Chief Operating Officer
|
Sell | 50.0K | $5.5M |
Page 1 of 1
Frequently Asked Questions
What is BioNTech SE's (BNTX) current stock price and consensus rating?
BioNTech SE (BNTX) is currently trading at $96.69. The consensus rating among 20 Wall Street analysts is predominantly 'Buy', with a score of 66 out of 100.
What is the median analyst price target for BNTX stock?
The median analyst price target for BioNTech SE (BNTX) is $126.35, which represents an upside potential of approximately 30.7% from its current trading price of $96.69.
How has BioNTech SE's revenue performed recently?
BioNTech SE (BNTX) has experienced a significant revenue decline of -59.5%. Current quarter revenue estimates project a further year-over-year decrease of -30.00%, indicating continued revenue contraction.
What are the key technical indicators for BNTX stock?
BNTX's technical indicators show bearish momentum, with an RSI at 19.5 (oversold) and the stock trading below its 50-day and 200-day moving averages ($96.94 and $97.63). Volume has also been below average.
What is BioNTech SE's profitability and valuation status?
BioNTech SE (BNTX) is currently loss-making with a negative EPS of -7.78 and a net profit margin of -63.64%. Its price-to-sales ratio of 9.37 is high compared to the sector median of 3.7.
Are insiders buying or selling BioNTech SE (BNTX) stock?
Insiders are net sellers of BioNTech SE (BNTX) stock. There have been no reported insider purchases, while total insider sales amount to $20.6 million across three transactions, signaling a moderate sell signal.
What is BioNTech SE's (BNTX) stock forecast for 2030?
Based on Monte Carlo simulations, BioNTech SE's (BNTX) stock forecast for 2030 includes a base case price of $175.92 and a downside case of $48.83. These are statistical outcomes, not guarantees.